Literature DB >> 28570834

In Vitro Antistaphylococcal Synergistic Effect of Isoflavone Metabolite Demethyltexasin with Amoxicillin and Oxacillin.

Johana Rondevaldova1, Jana Hummelova1, Jan Tauchen2, Ladislav Kokoska1.   

Abstract

Staphylococcal infections are often hard to treat due to increasing resistance, especially to β-lactams. Previous studies described the synergy between common antibiotics and isoflavonoids; however, little is yet known about the combinatory effects of antibiotics with products of human isoflavone metabolism. In this study, demethyltexasin (DT), a human body metabolite of soybean isoflavones, was evaluated for its possible antistaphylococcal combinatory effect with amoxicillin and oxacillin. For comparison, common therapeutically used combination of amoxicillin/clavulanic acid was tested. DT showed strong synergistic interactions against most of Staphylococcus aureus strains when combined with amoxicillin (sum of fractional inhibitory concentrations [ΣFIC] 0.257-0.461) and oxacillin (ΣFIC 0.109-0.484). When oxacillin was combined with DT, resistance to this antibiotic was overcome in many cases. Moreover, antibiotic/DT combinations were effective mainly against methicillin-resistant S. aureus (MRSA); however, the commonly used drug amoxicillin/clavulanic acid was effective only against sensitive strains. Our results indicated DT as a compound able to act synergistically with β-lactams. In addition, some combinations are effective against MRSA and decrease staphylococcal resistance. To the best of our knowledge this is the first report of the antimicrobial synergistic effects of isoflavone human body metabolite with common antibiotics. DT seems to be a possible candidate for further research focused on antistaphylococcal drug development, especially against antibiotic-resistant strains.

Entities:  

Keywords:  antibiotic resistance; antimicrobial combinatory effect; checkerboard method; β-lactam antibiotics

Mesh:

Substances:

Year:  2017        PMID: 28570834     DOI: 10.1089/mdr.2017.0033

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

1.  In vitro antagonistic inhibitory effects of palm seed crude oils and their main constituent, lauric acid, with oxacillin in Staphylococcus aureus.

Authors:  Klara Lalouckova; Eva Skrivanova; Johana Rondevaldova; Adela Frankova; Josef Soukup; Ladislav Kokoska
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

2.  Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli.

Authors:  Hye-Rim Kim; Yong-Bin Eom
Journal:  Antibiotics (Basel)       Date:  2021-02-05

3.  Molecular action of larvicidal flavonoids on ecdysteroidogenic glutathione S-transferase Noppera-bo in Aedes aegypti.

Authors:  Kazue Inaba; Kana Ebihara; Miki Senda; Ryunosuke Yoshino; Chisako Sakuma; Kotaro Koiwai; Daisuke Takaya; Chiduru Watanabe; Akira Watanabe; Yusuke Kawashima; Kaori Fukuzawa; Riyo Imamura; Hirotatsu Kojima; Takayoshi Okabe; Nozomi Uemura; Shinji Kasai; Hirotaka Kanuka; Takashi Nishimura; Kodai Watanabe; Hideshi Inoue; Yuuta Fujikawa; Teruki Honma; Takatsugu Hirokawa; Toshiya Senda; Ryusuke Niwa
Journal:  BMC Biol       Date:  2022-02-17       Impact factor: 7.431

4.  In Vitro Growth-Inhibitory Synergistic Effect of Zinc Pyrithione in Combination with Gentamicin against Bacterial Skin Pathogens of Livestock.

Authors:  Lucie Mala; Klara Lalouckova; Eva Skrivanova; Marketa Houdkova; Marie Strakova; Ladislav Kokoska
Journal:  Antibiotics (Basel)       Date:  2022-07-17

5.  The Antistaphylococcal Activity of Amoxicillin/Clavulanic Acid, Gentamicin, and 1,8-Cineole Alone or in Combination and Their Efficacy through a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Authors:  Soukayna Hriouech; Ahmed A Akhmouch; Aouatef Mzabi; Hanane Chefchaou; Mariam Tanghort; Bouchra Oumokhtar; Najat Chami; Adnane Remmal
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-28       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.